Pin1–FOXM1 inhibitors: a potential therapeutic for metastatic melanoma?
Saved in:
| Main Author: | Peter LJ de Keizer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2016-09-01
|
| Series: | Melanoma Management |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/mmt-2016-0010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis
by: Mohammad Amin Habibi, et al.
Published: (2025-06-01) -
Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study
by: Ken Horisaki, et al.
Published: (2025-04-01) -
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility
by: Jonas K. Oddershede, et al.
Published: (2025-04-01) -
Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01) -
The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies
by: Saber Imani, et al.
Published: (2024-11-01)